Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition

Fineline Cube Apr 1, 2026
Company Deals

Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform

Fineline Cube Apr 1, 2026
Company Deals

Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline

Fineline Cube Apr 1, 2026
Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Fineline Cube Mar 31, 2026
Company Deals

Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors

Fineline Cube Mar 31, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease

Fineline Cube Apr 1, 2026
Company Drug

Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy

Fineline Cube Apr 1, 2026
Company Drug

Shaanxi Panlong Receives Patents for Coronavirus 3CL Protease Inhibitor

Fineline Cube Dec 22, 2022

China-based Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864) has announced receiving two patents (US11518759B1,...

Company Deals

Sibionics Raises RMB 500 Million in Series D Financing Round

Fineline Cube Dec 21, 2022

Shenzhen-based chronic disease device maker Sibionics has reportedly raised close to RMB 500 million (USD...

Company Deals

Waker Bioscience Raises Angel Funding for ISA Technology Upgrades

Fineline Cube Dec 21, 2022

Waker Bioscience, an integration site analysis (ISA) specialist based in Shanghai, has reportedly raised “tens...

Drug

InnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination

Fineline Cube Dec 21, 2022

China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving approval from China’s Center...

Company Deals

Ronovo Surgical Raises Pre-Series B Funding for Surgical Robot Development

Fineline Cube Dec 21, 2022

Ronovo Surgical, a minimally invasive surgery device maker based in Shanghai, has reportedly raised “tens...

Company Deals Digital

PingAn Good Doctor Partners to Establish Lifestyle Medicine

Fineline Cube Dec 21, 2022

China-based PingAn Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good Doctor,...

Company Deals

JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development

Fineline Cube Dec 21, 2022

China-based JW Therapeutics Co., Ltd (HKG: 2126) has issued a stock exchange announcement revealing a...

Company Deals

Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm

Fineline Cube Dec 21, 2022

China-based Mabwell Bioscience (SHA: 688062) has announced the establishment of a licensing agreement with the...

Company Drug

Sirnaomics’ Lead Candidate STP707 Shows Promising Phase I Data

Fineline Cube Dec 21, 2022

Sino-US small interfering RNA (siRNA) specialist Sirnaomics (HKG: 2257) has revealed that its lead pipeline...

Company Drug

Kira Pharmaceuticals Gains NMPA and TGA Approvals for KP104 Phase II Study

Fineline Cube Dec 21, 2022

Sino-US biotech Kira Pharmaceuticals has announced receiving approvals from China’s National Medical Products Administration (NMPA)...

Company Deals

TowardPi Raises RMB 300 Million in Series C Financing Round

Fineline Cube Dec 20, 2022

China-based ophthalmology device maker TowardPi (Beijing) Medical Technology Ltd has reportedly raised close to RMB...

Company Drug

Aosaikang Receives FDA Approval for ASKG915 Clinical Trial

Fineline Cube Dec 20, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced receiving clinical trial approval for its...

Company Deals

Pfizer Exercises Option for Sisunatovir Rights with LianBio

Fineline Cube Dec 20, 2022

US major Pfizer Inc. (NYSE: PFE) has agreed with China-based LianBio (OTCMKTS: LIANY) to exercise...

Company Deals

Fosun Pharma Registers Comirnaty Vaccines in Hong Kong

Fineline Cube Dec 20, 2022

Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced that Comirnaty (BNT162b2) and Comirnaty bivalent...

Company Deals

XtalPi Partners with Singapore’s EDDC to Develop Lung Cancer Treatments

Fineline Cube Dec 20, 2022

Sino-US artificial intelligence (AI) firm XtalPi Inc. has struck a partnership with the Experimental Drug...

Deals

Prenetics Acquires Majority Stake in ACT Genomics to Boost Oncology Services

Fineline Cube Dec 20, 2022

Hong Kong-based Prenetics Global Ltd (NASDAQ: PRE) has announced the acquisition of a majority stake...

Company Drug

CStone’s Sugemalimab MAA Accepted by UK MHRA for NSCLC Treatment

Fineline Cube Dec 20, 2022

China-based CStone Pharmaceuticals (HKG: 2616) has announced that the Medicines and Healthcare products Regulatory Agency...

Company Drug

Ascletis Pharma Receives USPTO Notice for ASC10 Patent

Fineline Cube Dec 20, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving the Notice of Issuance from the...

Company Drug

HutchMed Initiates Rolling NDA Submission for Elunate to US FDA

Fineline Cube Dec 20, 2022

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the initiation of a rolling...

Legal / IP Policy / Regulatory

PCAOB Report Signals Relief for US-Listed Chinese Biotechs

Fineline Cube Dec 20, 2022

A report issued last week by the US Public Company Accounting Oversight Board (PCAOB) indicated...

Posts pagination

1 … 563 564 565 … 644

Recent updates

  • Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease
  • Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition
  • Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform
  • Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy
  • AstraZeneca Reports Positive Phase III Results for Efzimfotase Alfa in Hypophosphatasia Across Pediatric and Adult Populations
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease

Company Deals

Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition

Company Deals

Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform

Company Drug

Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.